New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:05 EDTCLDXCelldex price target lowered to $33 from $39 at Cantor
Cantor cut its price target on Celldex after the company discontinued development of CDX-1135 for dense deposit disease following unfavorable data. The firm, however, notes that the company intends to initiate six new clinical trials this year and expand a number of other trials. Cantor believes that this expansion of the company's clinical program will help offset the loss of CDX-1135. Cantor keeps a Buy rating on the shares.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
18:51 EDTCLDXCelldex 7.25M share Secondary priced at $24.00
Subscribe for More Information
February 24, 2015
16:00 EDTCLDXCelldex files to sell 7.25M shares of common stock
Subscribe for More Information
07:15 EDTCLDXCelldex reports Q4 EPS (36c), consensus (35c)
Subscribe for More Information
February 23, 2015
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCLDXCelldex rindopepimut receives FDA breakthrough therapy designation
Celldex Therapeutics announced that the FDA has granted rindopepimut Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM. This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment in December of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use